top of page
GFN_0081_edit.jpg

Harnessing the Natural Tropism of Mesenchymal Stem Cells to Cancer in A Drug Targeting Platform

elements&images_3.png

NanoGhost is a biotech company that develops a highly selective first-in-class drug targeting platform (Nano-Ghosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation.

​

NGs are nanovesicles equipped with inherent MSC targeting capabilities, ability to infiltrate inter and intra cellular niches, with versatile loading capacity and broad therapeutic applicability.

 

This technology is based on discoveries from the lab of Prof. Marcelle Machluf, Technion Institute of Technology, Israel.

Technology Overview
NanoGhost Platform Characteristics
The Israel's Ministry of Science and Technology acknowledged
NanoGhost platform as one of Israel's 60 most impactful
developments and discoveries
bottom of page